Ascendis Pharma A/S (ASND) |
| 224.11 -13.36 (-5.63%) 05-29 16:00 |
| Open: | 236 |
| High: | 236 |
| Low: | 218.675 |
| Volume: | 1,266,157 |
| Market Cap: | 13,845(M) |
| PE Ratio: | 25.47 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 250.27 |
| Resistance 1: | 237.26 |
| Pivot price: | 239.50 |
| Support 1: | 216.22 |
| Support 2: | 179.90 |
| 52w High: | 250.74 |
| 52w Low: | 160.86 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Financials
| EPS | 8.860 |
| Book Value | 9.160 |
| PEG Ratio | 0.00 |
| Gross Profit | 12.478 |
| Profit Margin (%) | 57.28 |
| Operating Margin (%) | 10.06 |
| Return on Assets (ttm) | -0.6 |
| Return on Equity (ttm) | 332.6 |
Company news
Fri, 29 May 2026
Ascendis Pharma slides 5.6% as investors digest recent run-up; no single headline catalyst apparent - Quiver Quantitative
Thu, 28 May 2026
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy) - Seeking Alpha
Wed, 27 May 2026
Ascendis Pharma (ASND) director Bienaimé buys 400 Ordinary Shares - Stock Titan
Mon, 25 May 2026
Ascendis Pharma A/S (ASND) Stock Analysis: Riding the Wave of Impressive Revenue Growth and Analyst Optimism - DirectorsTalk Interviews
Mon, 18 May 2026
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $240.5 - Moomoo
Mon, 18 May 2026
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate - ChartMill
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
